Table 17EORTC QLQ-C30 Symptom Subscale Scores

EORTC QLQ-C30 subscalesStudy 301

ravulizumab

N = 125

Study 301

eculizumab

N = 121

Study 302

ravulizumab

N = 97

Study 302

eculizumab

N = 98

Mean fatigue symptom scale score, n1251199494
  Baseline (SD)39.3 (22.75)37.3 (23.42)25.3 (22.63)26.3 (21.73)
  Week 26 (SD)19.1 (21.33)19.1 (18.57)20.2 (20.68)25.4 (23.37)
  Change from baseline to week 26 (SD)–20.2 (24.51)–18.6 (24.49)–4.97 (17.260)–0.71 (15.271)
Mean pain symptom scale score, n1241179594
  Baseline (SD)18.7 (23.44)15.3 (20.92)6.2 (15.84)8.3 (14.99)
  Week 26 (SD)7.3 (15.93)8.1 (16.46)7.2 (17.47)9.9 (18.82)
  Change from baseline to week 26 (SD)–11.3 (23.43)–7.6 (23.41)0.87 (12.722)1.42 (19.959)
Mean dyspnea symptom scale score, n1251199694
  Baseline (SD)27.2 (25.54)29.5 (25.89)11.7 (19.86)19.4 (25.29)
  Week 26 (SD)13.1 (19.80)12.6 (19.87)10.1 (18.80)18.1 (26.63)
  Change from baseline to week 26 (SD)–14.1 (24.78)–17.1 (25.99)–1.74 (18.950)–1.06 (20.417)

EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; SD = standard deviation.

Note: Outcome was outside of the statistical testing hierarchy and was evaluated in the full analysis set. Baseline was defined as the last non-missing value before the first dose of study drug.

Source: Clinical Study Reports for Study 301 and Study 302.1,2

From: Clinical Review

Cover of Ravulizumab (Ultomiris)
Ravulizumab (Ultomiris): CADTH Reimbursement Reviews and Recommendations: Therapeutic area: Paroxysmal nocturnal hemoglobinuria [Internet].
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.